Sheila Miknyoczki

Neurotrophins and Trk receptors in human pancreatic ductal adenocarcinoma: Expression patterns and effects onIn vitro invasive behavior

Sheila Miknyoczki, Deborah Lang, Lingyi Huang et al. · International Journal of Cancer · 1999 · 165 citations · Full text

Signal Transduction, Pancreatic Cancer, Malignant Disease +14

The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity

Sheila Miknyoczki, Hong Chang, Jennifer V. Grobelny et al. · Molecular Cancer Therapeutics · 2007 · 110 citations

The neurotrophin-trk receptor axes are critical for the growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice.

Sheila Miknyoczki, Weihua Wan, Hong Chang et al. · PubMed · 2002 · 91 citations

The Trk tyrosine kinase inhibitor CEP-701 (KT-5555) exhibits significant antitumor efficacy in preclinical xenograft models of human pancreatic ductal adenocarcinoma.

Sheila Miknyoczki, Hong Chang, Andres J. Klein–Szanto et al. · PubMed · 1999 · 84 citations

Pathology, Preclinical Xenograft Models, Cancer Biology +16

Pan-trk inhibition decreases metastasis and enhances host survival in experimental models as a result of its selective induction of apoptosis of prostate cancer cells.

Ashani T. Weeraratna, Sue Dalrymple, John C. Lamb et al. · PubMed · 2001 · 77 citations

Autocrine Production, Chemoprevention Strategy, Apoptosis +17